BioCardia, Inc. Capital Expenditures Incurred but Not yet Paid
BioCardia, Inc. (BCDA) reported Capital Expenditures Incurred but Not yet Paid of $2.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2018-05-10
- BioCardia, Inc. capital expenditures incurred but not yet paid for the quarter ending 2017-09-30 was -$3.00K.
- BioCardia, Inc. capital expenditures incurred but not yet paid for the quarter ending 2017-06-30 was -$10.00K.
- BioCardia, Inc. capital expenditures incurred but not yet paid for the quarter ending 2017-03-31 was $15.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month |
|---|---|---|---|
| 2017-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$13.00K derived: sum of 2 quarters · filed 2017-11-09 | $2.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $5.00K 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $15.00K 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |